Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea

• Published in: Human vaccines & immunotherapeutics Vol. 20; no. 1; p. 2348124
• Main Authors: Song, Youngji, Shim, Eunha
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 31.12.2024; Taylor & Francis Group
• Subjects: adjuvanted quadrivalent influenza vaccine; Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - economics; Aged; Aged, 80 and over; Cost-Benefit Analysis; Cost-effectiveness; Female; Humans; Influenza Vaccines - administration & dosage; Influenza Vaccines - economics; Influenza Vaccines - immunology; Influenza, Human - economics; Influenza, Human - prevention & control; Male; national immunization program; quadrivalent influenza vaccine; Quality-Adjusted Life Years; Republic of Korea; seasonal influenza; South Korea; Republic of Korea; quadrivalent influenza vaccine; adjuvanted quadrivalent influenza vaccine; South Korea; national immunization program; seasonal influenza; Cost-effectiveness

South Korea's National Immunization Program administers the quadrivalent influenza vaccine (QIV) to manage seasonal influenza, with a particular focus on the elderly. After reviewing the safety and immune response triggered by the adjuvanted QIV (aQIV) in individuals aged 65 and older, the Mini...